Roche Diagnostics Terminates Deal to Market Response Bio's Cardiovascular Panel | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics has terminated a sales and distribution deal with Response Biomedical after the Canadian diagnostic test maker failed to get US regulatory clearance of its cardiovascular tests on its most current platform, Response Bio announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.